- Cat #:
AGC-011
- Size:
50 µl, 0.2 ml
- Source:
Rabbit
- Type:
Polyclonal
|
|
Application:
IH, WB
|
|
Reactivity:
M, R
|
|
Application key: CBE- Cell-based ELISA, FC-
Flow cytometry, IC- Immunocytochemistry,
IE- Indirect ELISA, IFC- Indirect flow
cytometry, IH- Immunohistochemistry, IP- Immunoprecipitation,
LCI- Live cell imaging,
N- Neutralization, WB- Western blot
Species reactivity key: H- Human, M- Mouse,
R- Rat
|
|
Control antigen included
|
Lyophilized powder |
|
|
General information
|
|
|
L-Glutamate, the major excitatory neurotransmitter in the central nervous system, operates through several receptors that are categorized as ionotropic (ligand-gated cation channels) or metabotropic (G-protein coupled receptors). The metabotropic glutamate receptors family includes eight members (mGluR1-8) that have been divided into three groups based on their sequence homology, pharmacology and signal transduction.
Group II of the metabotropic glutamate receptors includes the mGluR2 and mGluR3 receptors. The receptors present the typical G-protein coupled receptor (GPCR) signature topology: seven transmembrane domains with a large extracellular N-terminus domain that contains the glutamate binding site, and an intracellular C-terminus one.1,2
mGluR2 and mGluR3 are coupled to Gi/Go and hence inhibit cAMP formation following receptor activation.1, 2
mGluR2 is widely distributed throughout the brain with high expression in several limbic areas including the cortex, hippocampus and amygdala. mGluR2 is localized primarily presinaptically, although postsynaptical localization has also been described.
In line with its presynaptical localization, mGluR2 is thought to function as an autoreceptor in a negative feedback mechanism that suppress further release of glutamate from the cell on which it is expressed.
The involvement of mGluR2 in neuronal excitability and synaptic transmission suggests that modulation of this receptor is a promising strategy for the treatment of neurological and neuropsychiatric disorders such as anxiety, schizophrenia, and pain.3,4
Alomone Labs is pleased to offer a highly specific antibody directed against an epitope located at the extracellular N-terminus domain of the rat mGluR2 receptor. The epitope is specific for mGluR2 and will not cross-react with the closely related mGluR3 channel. Anti- mGluR2 (extracellular) antibody (#AGC-011) can be used in Western blot analysis and immunohistochemical applications, and recognizes mGluR2 from rat and mouse samples.
|
|
| Western blot |
|
 |
| Western blot analysis of rat cerebellum (lanes 1 and 3) and cortex (lanes 2 and 4) membranes: |
1, 2. Anti-mGluR2 (extracellular) antibody (#AGC-011), (1:400).
3, 4. Anti-mGluR2 (extracellular) antibody, preincubated with the control peptide antigen. |
|
|
 |
| Western blot analysis of mouse brain membranes: |
1. Anti-mGluR2 (extracellular) antibody (#AGC-011), (1:200).
2. Anti-mGluR2 antibody, preincubated with the control peptide antigen. |
|
|
|
| Immunohistochemistry |
|
 |
| Expression of mGluR2 in rat brain |
| Immunohistochemical staining of perfusion-fixed brain frozen sections using Anti-mGluR2 (extracellular) antibody (#AGC-011). A. mGluR2 (green) is visualized in the corpus callosum (CC) and hippocampal stratum oriens (OR). B. Glial fibrillary acidic protein (GFAP) (red), a marker of astrocytes. C. Merge of the two images demonstrates expression of mGluR2 in astrocytes. DAPI is used as the nuclear counterstain (blue). |
|
|
|
|
|
|
| Immunogen |
|
| Peptide SLSRGADGSRHIC, corresponding to amino acids 109-121 of rat mGluR2 (Accession P31421). Extracellular, N-terminus. |
|
|
|
|
|
| Homology |
Mouse, human, dog, monkey - identical. |
|
| Purity |
Affinity purified on immobilized antigen. |
|
| Standard quality control of each lot |
Western blot analysis. |
|
|
|
| References |
|
| 1. Flor, P.J. et al. (1995) Eur. J. Neurosci., 7, 622. |
|
|
| 2. Conn, P.J. and Pin, J.P. (1997) Annu Rev Pharmacol Toxicol 37, 205. |
|
|
| 3. Swanson, C.J. et al. (2005) Nat. Rev. Drug Discov. 4, 131. |
|
|
| 4. Swanson, C.J. et al. (2005) Nat. Rev. Drug Discov. 4, 131. |
|
|
|
|
|
|
|
|
|
|
|
|
|